Avita Medical, Inc. · NASDAQ:RCEL
Avita Medical — Q2 2025 Earnings Presentation
16 slides from Avita Medical's earnings presentation, Aug 7, 2025
Slide 1: Second Quarter 2025 Financial and Business Update
Second Quarter 2025 Financial and Business Update August 7, 2025
Slide 2: Forward-Looking Statements & Legal Disclaimers
Forward-Looking Statements & Legal Disclaimers 2024.Q4 v9 This presentation and the accompanying oral commentary may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are predictions and subject to significant risks and un
Slide 3: Company overview
Company overview Jim Corbett Chief Executive Officer 3
Slide 4: Second Quarter Summary
Second Quarter Summary 1 Commercial revenue for the second quarter was $18.4, +21% vs Q2 2024 RECELL sequential growth impacted by transitory item: Gap in payments to providers using RECELL procedure CMS reimbursement delay temporarily impacts RECELL demand 2 A six-month backlog in unpaid provider c
Slide 5: RECELL Demand Impacted by CMS Reimbursement Gap, Recovery Expected in Q3
RECELL Demand Impacted by Centers for Medicare & Medicaid Services (CMS) Reimbursement Gap, Recovery Expected in Q3 Unpaid Provider Claims Impact on RECELL Recovery Underway • In January, CMS introduced This uncertainty impacted Q3 breakthrough: Multiple MACs new CPT codes for RECELL. RECELL perform
Slide 6: New Study Demonstrates Reduced Hospital Stay with RECELL
New Study Demonstrates Reduced Hospital Stay with RECELL Largest ever real-world study examined 6,300 patients from 2019-2024 Analysis at the British Burn Potential hospital cost savings from reduced length of stay* Association (BBA) annual meeting, June 2025 A recent real-world analysis of the nati
Slide 7: RECELL Changed Her Life: Abbey's Story Goes Global
RECELL Changed Her Life: Abbey’s Story Goes Global “Had 2nd and 3rd degree burns to my face (and my eyes I think). Had RECELL treatment done and the results were better than anybody could’ve expected.” The University of Colorado treated Abbey’s face and right arm with RECELL and grafted other areas
Slide 8: AVITA's Acute Wound Care Products Continues to Grow its Potential
AVITA’s Acute Wound Care Products Continues to Grow its Potential to Improve Outcomes and Reduce Length of Stay Cohealyx: autograft readiness in days rather than weeks represents a significant breakthrough First Peer-Reviewed Clinical Study showed fewer “days to graft” than competition Accelerating
Slide 9: Q2 2025: Portfolio Developments
Q2 2025: Portfolio Developments RECELL building towards standard of care in burn and expansion into trauma Two major hospitals expanding RECELL use to burns <20% TBSA; Potential to add ~150 additional patients/month from these sites. CMS approves New Technology Add-on Payment (NTAP) to RECELL for tr
Slide 10: Transforming Burn and Trauma Care in a $3.5B+ Total Addressable Market
Transforming Burn and Trauma Care in a $3.5B+ Total Addressable Market with Multi-Product Strategy 2019 2023 2025 Long-Term BURN-ONLY, BURN & TRAUMA, SINGLE- BURN & TRAUMA, MULTI- BURN & TRAUMA, MULTI- SINGLE-PRODUCT PRODUCT PRODUCT PRODUCT $455M $1.3B $3.5B >$3.5B TAM (U.S.) TAM (U.S.) TAM (U.S.) T
Slide 11: Financial overview
Financial overview David O’Toole Chief Financial Officer 11
Slide 12: Q2 Financials Reflect Growth, Cost Control, and Improved Operating Leverage
Q2 Financials Reflect Growth, Cost Control, and Improved Operating Leverage Revenue increase Operating expense reduction Net loss improvement Commercial revenue Operating expense Net loss USD million USD million USD million Decreased by Increased by 9.1% Decreased by 21% 35.7% 18.4 28.7 26.1 (15.4)
Slide 13: Full-Year Commercial Revenue Forecast and financial guidance
AVITA Full-Year Commercial Revenue Forecast and financial guidance Metric Previous guidance Updated guidance Full-year 2025 revenue $100m to $106m $76m to $81m Growth vs. FY2024 ~55% to 65% ~19% to 27% Cash flow break-even 2H 2025 Q2 2026 GAAP profitability Q4 2025 Q3 2026 13
Slide 14: Jim Corbett, Chief Executive Officer
Jim Corbett Chief Executive Officer 14
Slide 15: Takeaways
Takeaways Clear focus on executing our strategy With resolution in the AVITA’s financial forecast OrbiMed amendment Compelling reduction in backlog of claims updated to reflect secures long-term length of stay (LOS) is a underway, full demand recovery trajectory and alignment with AVITA’s key differ
Slide 16: Slide 16